1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

  • October 2015
  • 65 pages
  • ID: 3389018
In this report:
In the ##MM, urban China had the highest number of diagnosed incident cases (##,## cases) in 2014, and is expected to grow to ##,## cases by 2024 at a high AGR of ##.##%.
According to the International Agency for Research on Cancer (IARC), in 2012, almost one million new cases of gastric cancer occurred worldwide (##,## cases or ##.##% of the total cancer cases) (IARC, 2012).

Summary

Table of Contents

Search Inside

EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

Brief

Gastric cancer, also called stomach cancer, is a multifactorial disease that starts in the tissues lining the stomach. Gastric cancer usually begins in cells in the inner layer of the stomach and tends to develop slowly into the outer layer over various years. In the early stages of gastric cancer, the affected individuals exhibit symptoms including indigestion and stomach discomfort that require little medical attention and therefore, most of the cases remain undetected at the initial stages of the disease. Gastric cancer typically affects elderly individuals, ages 55 years and older, and peaks in the seventh decade of life and is twice as common in men as in women.

In 2014, there were a total of 312,520 diagnosed incident cases of gastric cancer in the 8MM. GlobalData epidemiologists forecast that the diagnosed incident cases of gastric cancer in the 8MM will increase to 364,518 cases by 2024 at an Annual Growth Rate of ~1.7 percent. In the 8MM, urban China had the more important number of diagnosed incident cases (134,968 cases) in 2014, and is anticipated to grow to 177,015 cases by 2024 at a high AGR of ~3.1 percent.

GlobalData epidemiologists' estimate for gastric cancer is supported by at least 10 years of historical data obtained from worldwide cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident gastric cancer cases were based on exhaustive age-specific and sex-specific trends in incidence in each of the 8MM. This forecast offers in-depth case-segmentation of the gastric cancer patient pool for each country by age, sex, and stage at diagnosis. On top of, GlobalData's analysis offers diagnosed incident cases of GEJ cancer and segmentation of diagnosed gastric cancer incident cases by cellular type and HER2 status. The forecast is driven by a thorough analysis of historical data. The forecast methodology was also constant across all the 8MM, thereby allowing for a meaningful comparison of the forecast diagnosed incident and 5-year diagnosed prevalent cases of gastric cancer across the 8MM.

Overview

- The Gastric Cancer EpiCast Report offers an overview of the risk factors, comorbidities, and overall trends for gastric cancer in the eight main markets (8MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, Japan (JP), and urban China). It includes a 10-year epidemiological forecast of the diagnosed incident cases of gastric cancer, gastroesophageal junction cancer, gastric adenocarcinoma, and the 5-year diagnosed prevalent cases of gastric cancer broken down by age and sex in these markets. Additionally this report offers farther segmentation of gastric cancer by stage at diagnosis, cellular type, and human epidermal growth factor receptor status.

- The gastric cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Great reasons to purchase

The Gastric Cancer EpiCast series will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall gastric cancer market.

- Quantify patient populations in the overall gastric cancer market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gastric cancer therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Gastric Cancer Global Clinical Trials Review, H2, 2017

Clinical Research in Gastric Cancer in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Gastric Cancer Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Gastric Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Gastric Cancer clinical ...

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H2, 2017

Clinical Research in Gastroesophageal (GE) Junction Carcinomas in H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, ...

The 2018-2023 World Outlook for Gastric Cancer Diagnostics, Screenings, and Treatments

The 2018-2023 World Outlook for Gastric Cancer Diagnostics, Screenings, and Treatments

  • $ 995
  • Industry report
  • April 2017
  • by ICON Group

This study covers the world outlook for gastric cancer diagnostics, screenings, and treatments across more than 190 countries.For each year reported, estimates are given for the latent demand, or potential ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.